Substance P Neuropeptide Promotes Prostate Cancer by Disrupting Antioxidant Defenses
Substance P increased oxidative stress in prostate cancer cells by reducing key antioxidant enzymes, while blocking its NK1R receptor with aprepitant reversed these effects.
Quick Facts
What This Study Found
Substance P/NK1R signaling increased ROS and decreased both the expression and activity of glutaredoxin and thioredoxin in PC3 and LNCaP prostate cancer cells. Aprepitant (NK1R antagonist) reversed all of these effects.
Key Numbers
The study measured changes in both expression and activity levels of glutaredoxin and thioredoxin proteins in response to SP/NK1R activation.
How They Did This
In vitro study using PC3 and LNCaP prostate cancer cell lines. Cells treated with Substance P and/or aprepitant (NK1R antagonist). Measured cell viability (resazurin assay), intracellular ROS levels, and glutaredoxin/thioredoxin expression (qRT-PCR) and activity (commercial kits).
Why This Research Matters
Substance P is elevated in many cancers. Understanding how this neuropeptide disrupts cellular antioxidant defenses reveals a new mechanism of cancer promotion and identifies NK1R blockade as a potential therapeutic strategy for prostate cancer.
The Bigger Picture
The nervous system and cancer are increasingly recognized as interconnected. Neuropeptides like Substance P can directly influence tumor biology. This study adds oxidative stress manipulation to the list of ways Substance P promotes cancer, and suggests that repurposing the anti-nausea drug aprepitant — already approved and well-tolerated — could have anti-cancer applications.
What This Study Doesn't Tell Us
In vitro study using established cancer cell lines, which do not replicate the complexity of tumors in the body. Aprepitant concentrations used in cell culture may not match achievable clinical doses. No animal or human data. The specific contribution of this redox mechanism to overall cancer progression is unclear.
Questions This Raises
- ?Does aprepitant reduce prostate cancer growth in animal models through this oxidative stress mechanism?
- ?Are Substance P levels elevated in prostate cancer patients, and does this correlate with tumor aggressiveness?
- ?Could combining aprepitant with standard prostate cancer treatments enhance their effectiveness?
Trust & Context
- Key Stat:
- Aprepitant reverses SP effects NK1R blockade restored antioxidant enzyme levels and reduced oxidative stress caused by Substance P in prostate cancer cells
- Evidence Grade:
- Preliminary evidence: in vitro cell line study demonstrating a specific mechanism. No animal or human data to confirm clinical relevance.
- Study Age:
- Published in 2024. Contributes to growing evidence on neuropeptide involvement in cancer biology.
- Original Title:
- The effect of SP/NK1R on expression and activity of glutaredoxin and thioredoxin proteins in prostate cancer cells.
- Published In:
- Naunyn-Schmiedeberg's archives of pharmacology, 397(8), 5875-5882 (2024)
- Authors:
- Zarei Shandiz, Sara, Assaran Darban, Reza, Javid, Hossein(4), Ghahremanloo, Atefeh, Hashemy, Seyed Isaac
- Database ID:
- RPEP-09625
Evidence Hierarchy
Frequently Asked Questions
What is Substance P and how does it affect cancer?
Substance P is a neuropeptide best known for transmitting pain signals. It also promotes inflammation and, as this study shows, can increase oxidative stress in cancer cells by suppressing antioxidant enzymes — creating conditions that favor tumor growth.
Could the anti-nausea drug aprepitant help fight cancer?
This cell study suggests aprepitant can counteract Substance P cancer-promoting effects by blocking the NK1R receptor. While intriguing, this is very early research — clinical trials in cancer patients would be needed before aprepitant could be considered for this purpose.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09625APA
Zarei Shandiz, Sara; Assaran Darban, Reza; Javid, Hossein; Ghahremanloo, Atefeh; Hashemy, Seyed Isaac. (2024). The effect of SP/NK1R on expression and activity of glutaredoxin and thioredoxin proteins in prostate cancer cells.. Naunyn-Schmiedeberg's archives of pharmacology, 397(8), 5875-5882. https://doi.org/10.1007/s00210-024-02996-x
MLA
Zarei Shandiz, Sara, et al. "The effect of SP/NK1R on expression and activity of glutaredoxin and thioredoxin proteins in prostate cancer cells.." Naunyn-Schmiedeberg's archives of pharmacology, 2024. https://doi.org/10.1007/s00210-024-02996-x
RethinkPeptides
RethinkPeptides Research Database. "The effect of SP/NK1R on expression and activity of glutared..." RPEP-09625. Retrieved from https://rethinkpeptides.com/research/zarei-2024-the-effect-of-spnk1r
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.